PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS ONE. 2008; 3(6): e2392.
Published online Jun 11, 2008. doi:  10.1371/journal.pone.0002392
PMCID: PMC2409220
Identifying Alternative Hyper-Splicing Signatures in MG-Thymoma by Exon Arrays
Lilach Soreq,1 Adi Gilboa-Geffen,2 Sonia Berrih-Aknin,3,4 Paul Lacoste,3,4 Ariel Darvasi,5 Eyal Soreq,6 Hagai Bergman,1 and Hermona Soreq2*
1Department of Physiology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel
2Department of Biological Chemistry, The Faculty of Science, The Hebrew University of Jerusalem, Jerusalem, Israel
3University Paris-Sud, UMR 8162, Hôpital Marie Lannelongue, Le Plessis Robinson, Paris, France
4CNRS, Le Plessis Robinson, Paris, France
5Department of Genetics, The Faculty of Science, The Hebrew University of Jerusalem, Jerusalem, Israel
6Bezalel Academy of Arts and Design, Jerusalem, Israel
Stefan Maas, Editor
Lehigh University, United States of America
* E-mail: soreq/at/cc.huji.ac.il
Conceived and designed the experiments: HS LS. Performed the experiments: LS AG. Analyzed the data: LS. Contributed reagents/materials/analysis tools: HS LS. Wrote the paper: HS LS SB ES. Other: General guidance: HB AD. Contributed thymus samples: PL SB. Contributed graphic models: ES.
Received February 22, 2008; Accepted March 27, 2008.
Background
The vast majority of human genes (>70%) are alternatively spliced. Although alternative pre-mRNA processing is modified in multiple tumors, alternative hyper-splicing signatures specific to particular tumor types are still lacking. Here, we report the use of Affymetrix Human Exon Arrays to spot hyper-splicing events characteristic of myasthenia gravis (MG)-thymoma, thymic tumors which develop in patients with MG and discriminate them from colon cancer changes.
Methodology/Principal Findings
We combined GO term to parent threshold-based and threshold-independent ad-hoc functional statistics with in-depth analysis of key modified transcripts to highlight various exon-specific changes. These denote alternative splicing in MG-thymoma tumors compared to healthy human thymus and to in-house and Affymetrix datasets from colon cancer and healthy tissues. By using both global and specific, term-to-parent Gene Ontology (GO) statistical comparisons, our functional integrative ad-hoc method allowed the detection of disease-relevant splicing events.
Conclusions/Significance
Hyper-spliced transcripts spanned several categories, including the tumorogenic ERBB4 tyrosine kinase receptor and the connective tissue growth factor CTGF, as well as the immune function-related histocompatability gene HLA-DRB1 and interleukin (IL)19, two muscle-specific collagens and one myosin heavy chain gene; intriguingly, a putative new exon was discovered in the MG-involved acetylcholinesterase ACHE gene. Corresponding changes in spliceosome composition were indicated by co-decreases in the splicing factors ASF/SF2 and SC35. Parallel tumor-associated changes occurred in colon cancer as well, but the majority of the apparent hyper-splicing events were particular to MG-thymoma and could be validated by Fluorescent In-Situ Hybridization (FISH), Reverse Transcription–Polymerase Chain Reaction (RT-PCR) and mass spectrometry (MS) followed by peptide sequencing. Our findings demonstrate a particular alternative hyper-splicing signature for transcripts over-expressed in MG-thymoma, supporting the hypothesis that alternative hyper-splicing contributes to shaping the biological functions of these and other specialized tumors and opening new venues for the development of diagnosis and treatment approaches.
Changes in gene expression, and particularly in alternative splicing patterns are often disease-associated [1], and aberrant alternative splicing (hyper-splicing) is one of the characteristics of cancer cells [2], as well as of inflammation and autoimmune muscle diseases[3]. The vast majority of human genes (>70%) are alternatively spliced [4], [5], and 75% of alternative splicing events affect coding regions, yielding subtle amino acid substitutions, removal of protein motifs or protein truncations [6]. This can alter protein structures, yield cell-specific protein patterns [7] and enlarge protein versatility in a tissue-specific manner [6]. However, tumor specific signatures of alternative hyper-splicing are still lacking, primarily since alternative splicing studies are based on expressed sequence tags (EST) or mRNA sequences [8], [9]. Poor coverage of low abundance transcripts [4], and uncovered tissues, disease states and developmental stages [10] hence call for the development of methodologies for identifying alternative hyper-splicing signatures in specific tumor types.
In search for tumor-specific alternative hyper-splicing signatures, we selected MG-thymoma, an epithelial tumor of the thymus gland [11] where lymphoid precursor cells differentiate into mature T-lymphocytes [12]. About one in three of all thymoma patients develop Myasthenia Gravis (MG), a neuromuscular autoimmune disease characterized by abnormal neuromuscular transmission [13], [14]. In MG, auto-immune antibodies against the muscle nicotinic acetylcholine receptor are accompanied by thymocytes hyperplasia. MG involves loss of acetylcholine receptors that initiate muscle contraction, which results in progressive muscle weakness. Overall, more than 60% of MG patients present a pathological thymus, including thymic hyperplasia in about 50% of patients and thymoma in 10 to 20% [14]. Understanding the role of alternative hyper-splicing of tumor-related, muscle-specific and immune function genes in the etiology of MG-thymoma can provide better diagnosis for patients and offer more hope for their treatments [15].
Linkage between regulated genes and the corresponding transcript quantities highlights tumor over-expressed transcripts as preferred targets for identifying hyper-splicing signatures [16]. We have recently used UniGene microarrays [17] to identify such over-expressed transcripts. However, those microarrays primarily detect the 3′-end of studied transcripts, disregarding transcript levels. Thus, Agilent [18] 60-mer probes are located between 150 to 1100 bps from the target transcript 3′-ends [18], whereas the 11 25-mer probes per gene of Affymetrix GC U133 Plus Arrays are located in a 600 bp range from these genes 3′-end [19]. Some of these limitations were overcome in the high-density lithography-based Affymetrix exon arrays [10], [20], where each transcript is interrogated by a large number of 25-mer probes [10] (50 in average), located according to its complete RefSeq annotation, and amplified RNA is prepared to cover the entire length of the analyzed transcripts. The massive increase in probes (~5.6 million), along with exon length-dependent probe numbers, enable unprecedented resolution into these genomic units. This ensures more robust detection of gene-level transcription changes [10] and allows the discovery of potentially new transcripts and novel, predicted exons.
At the functional level, alternative hyper-splicing can modify tumor properties, since gene products may play roles in multiple, often seemingly unrelated, routes. To approach these processes, tools for functional analyses of microarray data have been developed [21]. These primarily involved post-hoc functional analyses such as T-test, ANOVA [22] or clustering analyses [23] (i.e first finding lists of changed genes, by various computational methods, and then conducting functional enrichment analysis on these lists, e.g. EASE [24] and MAPPFinder [25]). However, translating a list of differentially expressed genes using annotation databases suffers from several limitations. Primarily, this approach overlooks transcripts that are involved in several biological processes. In addition, most downstream analysis tools for gene lists enable analyses of only one ontology abstraction level [21]. To address these difficulties, methods that allow ad-hoc detection of changed functional GO categories have been evolving. These largely use threshold-based statistical approaches (i.e. binomial, hypergeometric, chi-square or Fisher's exact test) that detect relative enrichments of gene categories given a population of genes [21]. However, they involve high incidence of false negatives that result from a unified, often arbitrary threshold [26], [27].
To increase the range of solutions and enable detection of subtle and non-trivial changes, several threshold-free methods were developed (for example, GSEA [28] and a program based on semantic similarities among GO terms [29]). These are based on the Kolmogorov-Smirnov (KS) goodness-of-fit test [27], [28], [30], [31], which prevents neglecting most of the collected data but may be more error-prone to false positives. Although rank-based methods have been suggested [32], [33], the important conceptual advantage of threshold-freedom lies in considering gene expression data simultaneously, without the uncertainty associated with prior gene list extraction [26]. Combining both discrete and continuous data analyses to detect changed functional gene GO categories from expression data can thus provide several advantages for analyzing microarrays [27].
We applied an ad-hoc method for multileveled testing of GO categories enrichment in exon array-derived data sets by combining a KS and Fisher Exact (Hypergeometric), with detailed term-to-parent statistical analysis on the GO categories represented on the arrays. First, we analyzed our in-house MG-thymoma study and the Affymetrix colon cancer [10] exon microarray data set, which identified tumor-specific alternative splicing events relevant to both tumors or specific to one of them. In-depth analyses of exon-specific alterations involved several key transcripts from the tumor-related, immune function and muscle-characteristic GO categories and the MG-related ACHE gene, which is ubiquitously expressed, undergoes alternative splicing at both termini (3′ and 5′) and contributes to many different biological processes [34].
To study the contribution of alternative splicing to tumor biology, we developed a novel approach for identifying alternative hyper-splicing signatures. Using human exon microarrays, we compared MG-thymoma tumors from patients with MG to Affymetrix datasets from healthy tissues and colon cancer. Combined ad-hoc and post-hoc statistics with in-depth analysis of key transcripts and FISH, RT-PCR and mass spectrometry followed by peptide sequencing validation revealed pronounced alternative hyper-splicing in several gene categories modified in MG-thymoma tumors. These spanned tumorogenic, immune function and muscle-specific transcripts, involved reduced expression of the splicing factors ASF/SF2 and SC35 and extended into the discovery of a putative new exon in the MG-involved ACHE gene. Together, these findings support the notion of a major contribution of alternative hyper-splicing to MG-thymoma features, opening new venues for diagnosis and treatment of specific tumor types, and revealed specific tumor-type alternative splicing signatures reflecting MG-thymoma and colon cancer properties.
To identify tumor-specific changes in gene expression, we used in-house data of cortical thymoma tumors from MG patients and normal thymuses and the Affymetrix sample data set [20] of colon cancer versus normal colon and other healthy tissues. We applied an integrative functional ad-hoc analysis method to gene-level summary signals (median core probe sets or PLIER signal estimates [10], [20]). Each term was compared to the global array population and to all its direct parent GO terms as well as to the root of the tree: Molecular Function (MF) or Biological Process (BP) (Figure 1). Additional statistical tests of location involved the Kruskal-Wallis and variance tests. Within the categories that changed specifically compared to their parent GO terms we searched for genes containing core probe sets that changed by more than 4-fold between MG-thymoma to control thymuses.
Figure 1
Figure 1
Exon array analysis workflow-gene-level signals are calculated from normalized exon array CEL files by summarizing probe sets signals (either by PLIER or any other gene level summary method).
Iter-PLIER gene-level data of Affymetrix colon cancer data set [20] (data will be given upon request) served for comparison of the detected genes. In addition, we tested the sensitivity and specificity of our ad-hoc approach by conducting it on the colon cancer data set (results under Table S1) and found a wide overlap of tumor to normal tissue data compared to other colon cancer 3′ microarray analyses and one proteomic data set. This revealed a higher level of accuracy, superior to others' published data sets in both post- and ad-hoc approaches [20], [24], [35][37] (Text S1). We detected 100% of the categories identified by all the other methods, at the significance levels of 0.05 and 0.001. Our total findings overlapped with others ranged at 31–90%, with the closest (90.91%) achieved by comparison to post-hoc analysis we applied on the Affymetrix colon cancer exon array data set [20], [24], [35][37], making false negatives unlikely. Importantly, 56.63% of the categories detected by us at significance level of 0.01 were also detected by one or more of the compared methods (Text S1), which exhibited lower overlap ratios among them (26.74–43.97%). One functional bioinformatics post-hoc method was similar to ours in detection ratios compared to the other methods (56.76%) [35].
Global continuous and discrete term analyses reveal MG-thymoma affected GO terms
To search for the molecular changes that underlie MG-thymoma we applied our ad-hoc functional analysis and compared each GO term to the global array population. We observed ample changes in both BP and MF categories (Figure S1). Noticeably, more categories decreased according to both approaches; compatible with the exon and gene level changes, also when compared to the colon cancer data set (Text S2, Figure S2) and with the decrease in GO categories in hyperplasic thymuses [38]. Permutations of both MG-thymoma and colon cancer data sets verified those global expression change difference (Figure S3). In both MG-thymoma and colon cancer data sets, we found differences between expression changes in the 3′ compared to 5′ at the whole genome level (Text S2, Figure S45). Noticeably, MG-thymomas showed increase in muscle contraction (P<0.05 by both discrete and continuous methods, Table S2) both in this and in our previous study [38]. Totally, 85 BP and 97 MF categories exhibited a change in MG-thymomas compared to healthy thymuses. Predictably, more categories were detected by the continuous approach as compared with discrete analyses (Text S2). Nevertheless, decreased MF categories showed an almost total overlap between the two methods.
Specific hierarchical term to parent analyses in MG-thymoma
Each term represented by the array transcripts was compared to its direct parent terms in the GO tree, as well as to its tree root (MF/BP), using both continuous and discrete data analyses, as well as tests for location and dispersion (Table S3). Several key categories were found to be changed. These included RNA binding, which changed (Figure S6) compared to two parent terms (MF): transcriptional repressor activity (decreased, P = 0.01 in the continuous method, with changed dispersion and location, P<0.05) and compared to complement receptor activity (with a change in dispersion, P<0.01). Cell cycle terms showed both decreases and increases compared to its direct parent, cellular physiological process (P<0.005, BP). More GO categories changed compared to their direct parent terms (i.e specific analysis) than compared to the whole array population (i.e global analysis), identifying specific GO levels that changed and pointing at specific disease-related genes.
Finding disease-relevant genes in MG-thymoma by combining term to parent analysis with threshold on core exons
We used the results of our specific term analysis to search for core exons with a cutoff threshold of 4–6 fold difference between patients to healthy subjects. We identified 20 genes belonging to the tumor-related, immune function and muscle-specific categories (Table 1). To these we added ACHE, which expresses at low levels but is highly relevant to MG [38], [39]. Figure 2 presents these changes as color-coded clusters highlighting the alternative splicing modifications. The MF and BP categories to which the genes belong and corresponding term-to-parent changes are listed under Table 2 and and3.3. COL11A1 (Figure 3), extracellular matrix structural constituent, changed compared to its two direct parents (Figure S6). COL11A1 was up regulated in MG-thymoma (4–6 fold in a large number of core probe-sets) and more moderately in colon cancer compared to healthy colon (Figure 3A–J J and Text S3). Its first known exon was expressed in the colon but not the thymus, whereas in MG-thymoma an extended probe set located just before the first exon was highly expressed (Figure 3K), indicating alternative splicing in this large (0.2 Mb) gene. Another collagen, COL1A1 (skeletal development, BP), is notably involved in chronic inflammation [40]. COL1A1 was up-regulated in MG-thymoma compared to healthy thymuses and in colon cancer compared to healthy colons. The tumor-related genes included the tyrosine kinase receptor ERBB4 (cell proliferation, nucleotide binding, MF) which was up-regulated in MG-thymoma (Text S3) and is de-regulated in many human tumors [41]. In contrast, the growth factor dermatopontin (DPT), which belongs to cell adhesion and protein binding, was down-regulated in both cancer types (Figure 4A).
Table 1
Table 1
Targeted MG-thymoma genes
Figure 2
Figure 2
MG-thymoma targeted genes identified as subject to major changes in MG-thymoma tumors by specific, term-to-parent, ad-hoc combined statistical analyses and ACHE.
Table 2
Table 2
MF Specific changed GO terms compared to their parent GO terms in MG-thymoma
Table 3
Table 3
BP Specific changed GO terms compared to their parent GO terms in MG-thymoma
Figure 3
Figure 3
Detailed expression map of COL11A1 in MG-thymoma and colon cancer.
Figure 4
Figure 4
Detailed expression map of HLA-DRB1, CTGF and DPT in MG-thymoma and colon cancer.
Connective tissue growth factor (CTGF) was up-regulated in MG-thymoma compared to control thymus, control colon and colon cancer samples (Figure 4B). The low expression levels of its second exon in MG-thymomas may indicate exon skipping. CTGF belongs to 4 modified MF GO categories: protein binding, DNA replication, cell motility and epidermis development. Also in protein binding as well as in cell adhesion and transmission of nerve impulse (decreased, BP) is CNTNAP2, which exhibited over 4-fold increase in 4 core probe-sets. CNTNAP2 was highly up-regulated in MG-thymoma, exhibited low expression in colon compared to thymus, and was down–regulated in colon cancer (Text S3). Its 3′ exons are expressed only in MG-thymoma and not in healthy thymus, suggesting an alternative terminus. LPHN3 (also known as LEC3), encodes a receptor activity member of the latrophilin G-protein coupled receptors (GPCR). LEC3 was up-regulated in MG-thymoma, but down-regulated in colon cancer (Text S3), Similar to Adenylate cyclase (ADCY2, magnesium ion binding), and the iroquise homeobox gene IRX2, (transcription factor activity). In proteolysis, we identified the subtilisin PCSK2, with 4-6 fold increases in 8 of its core probe-sets in MG-thymoma and increases in colon cancer (Text S3), and the endopeptidases PHEX and ADAMTS20 (proteolysis), both up-regulated in MG-thymoma but not in colon cancer (Text S3). In the BP category immune response we found the histocompatibility MHC-II complex gene HLA-DRB1 (Figure 4C). Its expression is significantly higher in thymus compared to colon, with a putative 5′ end-modified HLA-DRB1-002 transcript in MG-thymoma [42]. Interleukin (IL) 19 expressed higher in thymus than colon (Text S3) and increased in MG-thymoma. Also, SEMA3D (cell differentiation) was highly up regulated in MG-thymoma but not colon cancer (Text S3). The solute carrier SLC7A10 (changed transport, BP), an inflammatory and apoptosis modulator [43], increased both in MG-thymoma and in colon cancer, with higher thymus than colon expression (Text S3).
The tRNA synthetase, EPRS, expressed higher in thymus than in colon, belongs to 5 specifically changed MF GO categories: binding, ATP binding, ligase activity, glutamyl-tRNA aminoacylation and protein complex assembly. It was up-regulated in both MG-thymoma and colon cancer, as well as in different cancer types [44]. Also in ATP binding, the fibroblast growth factor receptor FGFR4 showed over 4-fold decrease in two core probe-sets in MG-thymoma (Text S3). FGFR4 also belongs to protein serine/threonine kinase activity and receptor activity. The cytochrome P450 CYP4X1 gene (monooxygenase activity, electron transport) increased in MG-thymoma compared to healthy thymuses, with higher thymus than colon expression and increases in colon cancer as well (Text S3).
The muscle-specific myosin MYH14 (nucleotide binding, motor activity, MF) exhibited higher expression levels in the thymus than other examined tissues (Text S3). It exhibited alternative splicing in MG-thymoma tumors compared to healthy thymuses but not between colon cancers to normal colons (Text S3). The initial exons showed higher levels in MG-thymoma where its middle-end exons were higher in normal thymus. This suggests the existence of alternative variants of MHY14 in MG-thymoma compared to normal thymuses. In addition, we observed a prominent median gene-level increase in MG-thymoma compared to normal thymuses (Text S3). We also detected an increase of Myosin in MG-thymoma using Immunohistochemistry validation with antibody specific to Myosin (Figure 5A). Indeed, MG patients produce antibodies against structural muscle proteins, among them myosin [45] and Myosin previously showed a change immuno-histochemistry [46].
Figure 5
Figure 5
mRNA and protein expression of splicing factors ASF/SF2 and SC35, Myosin and ACHE.
Decreased SC35 and ASF/SF2 in MG-thymoma
Alternative splicing is modulated by the serine-arginine (SR)-rich protein SC35 [47], [48] (also known as SFRS2, splicing factor, arginine/serine-rich 2, ENSG00000161547), which interacts with different proteins, including ASF/SF2 (SFSR1, ENSG00000136450) [49]. FISH and Immunohistochemistry exhibited SC35 and ASF/SF2 decreases in the MG-thymoma tissues (Figure 5A and Figure S7), compatible with the findings of others [50]. Intriguingly, at the exon expression level ASF/SF2 is higher in both healthy thymus and MG-thymoma, than in all other examined tissues [51]. SC35 is also higher in thymus than in all other examined tissues. However, both SC35 and ASF/SF2 are down-regulated in inflamed muscle [52], and both showed down-regulation in MG-thymoma (Figures 5B, C and Text S3). Moreover, two SC35 exons show higher expression than the 3′ UTR domain, suggesting alternative splicing.
A new putative ubiquitously expressed exon in the ACHE gene
FISH for AChE-R protein variant indicated a significant increase in the number of stained cells in the MG-thymomic section compared to healthy thymus (Figure 5A). The largest constitutive exon of number 2 of ACHE (Figure 6A,C) showed pronounced expression compared to the other ACHE exons in exon array data sets from cerebellum, breast, liver, muscle, kidney, heart, pancreas and both normal and tumor colons (Figure 6A, gene structure under 6B). The mRNA levels of the constitutive exon 2 in the thymus, and yet more so in MG-thymoma tumors were higher than in all other examined tissues (Figure 6A–C) with mean signal intensity of 528.5 in MG-thymoma and 386.5 in healthy thymuses compared to mean signal intensity of 158.9 in colon cancer and 223.6 in healthy colon and 261.3 in healthy pancreas, the highest expression compared to all the other normal tissues. We found changes in two different categories to which ACHE belongs: response to wounding (BP) decreased according to the discrete approach compared to both response to external stimulus and detection of bacteria and compared to response to external stimulus (Table S3). Muscle contraction (BP) globally increased according to both the discrete approach (P = 0.02) and to the KS test (P = 0.01), compatible with our recent report [38]. Specifically, it changed compared to its direct parent terms: organismal physiological process, taxis (increased according to the continuous approach with a change in location, and decreased according to the discrete approach) and establishment of localization (increases and decreased according to the discrete approach).
Figure 6
Figure 6
ACHE gene structure, alternative transcripts and protein products, and the discovery of a Novel ACHE exon.
In-depth analysis of the expression levels of all ACHE probe-sets (core, extended and full) in MG-thymoma yielded two potentially new exons. These ACHE exons also appeared in exon array data sets from colon cancer and multiple healthy tissues [10], [20]. One of the predicted ACHE exons (located in the intron between the constitutive exon 3 and the alternative exon 4) showed values close to those of the constitutive exon 2 (Figure 6A and 6C). Real-time and quantitative RT-PCR analyses of this exon confirmed expression (Figure 6D), and sequencing of the amplified intronic region validated its identity (Figure 6E and 6F). Repeat Masker [53] demonstrated multiple ALu repeats in the intron where this exon lies (intron 2–3, Text S4), suggesting ALu exonization [54], which may lead to a prematurely terminated or smaller ACHE product.
Linking MG-thymoma exon array expression changes with proteomic analysis
The number of proteins expressed in mammalian tissues far exceeds that of the corresponding transcripts, likely due to alternative splicing [7], which expands the proteome by several orders of magnitude [55]. To link exon array data to protein products, we used MS of proteins from tested tissues, followed by functional annotation of the detected categories. The procedure is described under supplementary material[56]. Peptide sequencing obtained from 1D gel analysis of MG-thymoma and control thymuses (DataSet S1) yielded 91 proteins showing MG-thymoma-associated changes. These were divided into four groups using K-Means implementation according to fold changes between MG-thymoma and controls. Of these, about half demonstrated peptide sequences potentially belonging to more than one isoform, corroborating the exon array indications for alternative splicing. These included annexin A2, fibrinogen, chaperonin, heat shock protein, lamin A/C and DEAD box polypeptide 17, to name a few (Figure 7A and B).
Figure 7
Figure 7
Proteomic Analysis Combined with Exon Array Data Indicates Possible Alternative Splicing and Overlaps with Changed GO Categories.
Using the number of detected peptides as protein signals, we compared protein changes in the exon array and MS data. Many of the detected proteins shared MF and BP GO terms identified in our arrays (for example, both enolase and nucleolin share the muscle development category), and overlapping changes were observed in binding (Figure 7A). Thus, valosin-containing protein (VCP, marked as Valosin in Figure 7) increased, both in the MS and according to the exon array analysis (Figure 7B). VCP contributes to ATP-dependent cellular processes and is required for the survival of breast cancer cells [57]. The ezrin, radixin and moesin proteins, involved in intracellular anchoring of cell membrane proteins to the cytoskeleton [58], were detected by both the MG-thymoma MS samples and the exon arrays (Figure 7B). MG-thymoma radixin median exonic change increased but ezrin and moesin decreased, reflecting specific regulation for each member of this protein family. Inversely, fibrinogen was only observed in control samples, perhaps indicating its de-stabilization in the tumors.
Taken together, the RT-PCR, FISH and MS validation tests were all supportive of the exon array findings of massive changes in alternative splicing, in spite of the inherent limitations in each of these methods (e.g. the requirement for tissue preservation, variable primer efficiencies and limited resolution power of peptide sequencing).
We combined exon Arrays with ad-hoc and post-hoc statistics, in-depth analysis of key modified transcripts and multi-leveled validation tests to identify a hyper-alternative splicing signature for MG-thymomas. Our findings highlighted hyper-splicing in tumor-related, immune function and muscle-specific transcripts with distinct patterns from those of colon cancer or healthy thymus and included parent-child relationships in the GO hierarchy [59], [60], which specifically highlighted biologically significant categories and transcripts. Comparison to other available microarray analysis techniques [61] demonstrated higher detection rate and greater accuracy of our approach. Importantly, ASF/SF2 and SC35, previously shown as proto-oncogens [62] exhibited highest mRNA expression levels in the thymus then other tissues yet decreased in MG-thymoma compared to healthy thymus at both the protein and mRNA levels. Changes in the expression of these proteins can affect the alternative splicing of an undefined number of cellular transcripts and might account for some of the known splicing changes in cancer [63][65]. Our findings thus suggest aberrant tissue- and cancer-specific decline in alternative splicing, accompanied by alternative hyper-splicing. Specific changes related to MG-thymoma included HLA-DRB1, associated with a haplotype predictive of MG susceptibility in female [66] with specific gene variants. Up until now, the association between MG-thymoma to MHC haplotypes spanned a thymoma-associated class II allele on the DQB1 haplotype [67]. Also, B7, B8 (in early MG [68], [69]), DR3 (in early MG [67]), DR1, protective in MG [67] and the DR2 allele [15] all showed associations to MG. Our findings are hence indicative of alternative HLA-DRB transcript(s) as being involved.
We found general increases in muscle-related GO terms and increased myosin levels (both mRNA and protein). The mRNA increase was significant both in MYH14 and in MYH10. A possible splice shift observed in MYH14 gene, as compared to decrease of it mRNA in colon cancer. Indeed, antibodies against structural muscle proteins, among them myosin, were detected by others in the sera of MG patients [45], and myosin mutations are associated with colon cancer [70], [71].
For cancer to metastasize from a primary tumor, the extracellular matrix-physiological barrier whose primary structural constituent is collagen-must be degraded to allow the passage of tumor cells. Collagen is further involved in the immune response to metastasis [72]. In the collagen COL1A1 gene, we detected up-regulation in both MG-thymoma and colon cancer. Another collagen important for cartilage collagen formation and for organization of the extracellular matrix [73], COL11A1, was up-regulated in MG-thymoma, perhaps reflecting a compensation mechanism(s) over the degradation of its protein product. The diverse expression levels of core exon probe sets in COL11A1 between colon cancer and MG-thymoma tumors may unveil many unknown smaller transcripts, relevant to different types of cancer. Currently, most of cancer research is conducted using standard 3′ arrays, which are limited in their discovery scope. Our study highlights potential benefits from using high-resolution arrays in the study of cancer. Importantly, type I collagen reduces DPT mRNA levels [74], and DPT was down-regulated both in MG-thymoma and in colon cancer, suggesting inter-relationship between the observed changes.
Other MG-thyoma increased transcripts included the latrophilin LPHN3, which may function in both cell adhesion and signal transduction, processes that are both essential in tumorigenesis [75]. Also, IRX2, involved in the regulation of developmental processes via the WNT pathway and which is notably amplified in soft tissue sarcomas [76] was overexpressed. CNTNAP2, an exceptionally large gene which encompasses almost 1.5% of chromosome 7, and which functions in the vertebrate nervous system as both a cell adhesion and a receptor molecule [77] was increased as well. In most of these genes, we observed MG thymoma-associated alternative hyper-splicing events (Figure 2).
We selected the low-level expressed ACHE gene for challenging the resolution power of the Exon array technology. In both MG-thymoma and control thymuses, we detected both the predictable 3′ alternative splicing and a previously unknown exon between introns 3 and 4, validated using RT-PCR, real-time RT-PCR and sequencing on MG-thymoma samples. In-depth analysis of Affymetrix exon array data sets suggests ubiquitous expression of this novel exon, which likely originated by ALu exonization (AF8 and [54]). Further studies will be required for exploring the biological significance of this finding, for example under stress conditions or in neurodegenerative disease, where ACHE gene expression is altered [7], [78]. For example, inclusion of this exon may cause early terminated translation, yielding a shorter polypeptide with yet unknown stability and biochemical features. Parallel not yet known ALu -derived exons likely exist in numerous other genes[30], which calls for further exon array studies to establish the scope of this phenomenon at the post-transcriptional level.
MS and peptide sequencing of the MG-thymoma samples analyzed by exon arrays, followed by clustering of identified proteins enabled linking these data to median core gene-level changes and corresponding GO terms. Overall, the MS results were compatible with a complex pattern of regulation for specific exons, genes and protein products. Median core exonic changes thus corresponded well with tissue detection of relevant mRNAs and proteins, even for relatively rare products such as AChE-R. The MS approach enables simultaneous targeting of numerous proteins, but with limited resolution compared to that of exon expression arrays. Only major proteins are detectable, and these randomly break into peptides and may be falsely identified by the upper layer alignment software because only one or two peptides can be observed. Notably, MS-detected proteins sharing the same GO categories showed interactions with exon-array analysis results, suggesting networks relating to the examined disease. Additionally, proteins sharing one biological process are more likely to interact than proteins involved in distinct processes [79]. Also, dis-similarities between mRNA and protein changes may indicate measurement errors, post-translational events, distinct turn-over rates or alternative splicing. In contrast, FISH and immunohistochemistry are highly sensitive, albeit limited in scale, thus enabling identification of subtle yet specific mRNA and protein changes.
Combining exons, whole transcripts and functional analyses with protein data and available exon array data sets can add further support to exon array studies. In view of the complexity of alternative splicing processes, our finding of a clear hyper-splicing signature for MG-thymoma suggests physiological significance for this signature. This, in turn, supports a notion whereby such exon-array derived signatures can serve for diagnosis as well as for rational drug design. The information provided by exon array experiments thus expands our biological knowledge on known and new transcript variants, opening new potential avenues for research, diagnosis and therapeutics.
Human thymus tissue samples
Freshly discarded thymic fragments were obtained from immunologically healthy female and male patients undergoing corrective cardiovascular surgery or from MG patients undergoing prophylactic thymectomy at the Centre Chirurgical Marie Lannelongue (Le Plessis Robinson, France). All MG patients included in the study were treated with anticholinesterases but not with corticosteroids or immunosuppressors. Thymoma tissues were removed for therapeutic purpose and fragments of normal thymus tissues were removed to make the large vessels more accessible during cardiac surgery. Pathologists at the Centre Chirurgical Marie Lannelongue (Le Plessis Robinson, Paris, France) determined the classification of thymoma. The Institutional Review Board: Comité de Protection des Personnes de Kremlin-Bicêtre approved the use of human tissues based on verbal consents alone. Our IRB explained that written informed consents were not mandatory, since the tissues were initially harvested for therapeutic purposes and because all donors remained anonymous. Samples are described under Table S4.
RNA isolation
RNA was extracted from frozen thymus samples using the RNeasy lipid tissue kit (Qiagen, Valencia, CA) as per manufacturer's instructions from healthy and pathological thymus samples. DNase treatment was applied to avoid DNA contamination. RNA integrity was confirmed by gel electrophoresis, and RNA concentration and purity were assessed spectrophotometrically.
Human exon 1.0 ST microarray experiment
1 µg of total RNA from MG-thymoma (male, 44 and female, 53), control (male, 43 and female, 46) thymuses was labeled with the Affymetrix exon array whole transcripts sense targeting labeling assay and reagents, including r-RNA reduction and labeling with Streptavidin-phycoerithrin. Each sample was hybridized to a GeneChip® Exon 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) according to manufacturer's instructions, and results scanned to create four .CEL files using Affymetrix GCS 3000 7G scanner and GeneChip Operating Software v. 1.3 to produce .CEL intensity files.
Additional exon array data files and normalization
Human colon cancer and all other available tissues sample data sets of Affymetrix exon array in .CEL files were downloaded from Affymetrix web site (http://www.affymetrix.com/support/technical/sample_data/exon_array_data.affx).
The data was normalized using Affymetrix ExACT software to sketch normalize exon array data. Probes of all the probe sets (core, extended and full) were summarized using ExACT [80]. Gene-level iter-plier results are given under ST1. Each exon array probe-set is annotated in one of three possible levels: core, extended and full, according to the annotation source of the interrogated region. Core probe sets are supported by most reliable information, associated with full-length coding sequence mRNA evidence from RefSeq and GenBank records. Extended transcript clusters are based on cDNA evidence and include other human mRNA and EST sequences, ENSEMBL gene collections, synthetically mapped mRNAs from mouse and rat, mitoMap mitochondrial genes, microRNA registry genes, vegaGene and vegaPseudoGene records. Full Transcript Clusters are supported by gene and exon prediction algorithms including GeneID [81], GenScan [82], GenScanSubOpt [83], exoniphy [84], RNAGene [85], sgpGene [86] and Twinscan [87]. Each probe set contains several probes (typically 4) [10].
Statistical data analysis and bioinformatics
Functional GO analysis
Mapping of transcript clusters to UniGene identifiers
Transcript cluster IDs were assigned to their corresponding UniGene clusters using transcript_annot file [80]. For each transcript, all the UniGenes that are included in its region were considered for further functional analysis.
Mapping of UniGene identifiers to corresponding GO terms
EASE [24] program served to identify all of the BP and MF GO terms that are represented on the human 1.0 ST Exon array. GO ontology files (www.geneontology.org) enabled defining of all the UniGenes (UG) associated with each represented GO term. Statistical tests found increases or decreases in expression using the discrete Fisher exact test with a 2-fold threshold, and continuous KS statistics, analyzing each tail separately.
Colon cancer exon array data set [20] functional analysis
20 samples of colon cancer and healthy colons [20] (N = 10 in each) were analyzed. For gene level analysis, we used iter-PLIER [80] gene level transcript signals of the colon cancer data set published by Affymetrix [20]. We calculated the mean log ratio, and coefficient variation (CV) score for each group (data available upon request). UniGene identifiers and their corresponding signals were analyzed using continuous and discrete GO analysis using KS and Fisher exact test, respectively.
Colon cancer arrays comparison using GO analyses
From colon cancer exon array data [20], changed genes (N = 159) obtained from Affymetrix quantile sketch normalization and ANOVA p-values and fold changes[20]. We applied EASE [24] to obtain enriched BP GO categories.
Enriched BP GO categories in the list of changed genes in colon cancer, using microarray analyses, obtained from Bush and coworkers [35], where ErmineJ [33] was used to analyze GO of 1975 differentially expressed probesets identified by the empirical Bayes HotellingT2 model [35]. GO analyses of protein maps obtained by 2D gel MS analysis of colon cancers were obtained from Patel and coworkers [37]. A list of changed BP GO categories using functional analysis of colon cancer using microarrays was obtained from Maglietta and coworkers [36]. Full results table will be given upon request.
MG-thymoma exon array data set functional analysis
UG identifier lists were extracted and then GO [88] annotations of these lists were obtained by EASE [24]. To obtain gene level signals, the median core exonic fold change of each UG cluster was calculated. UG identifiers and their corresponding signals were grouped into their corresponding GO terms, and analyzed using continuous and discrete GO analysis using KS and Fisher exact test, respectively, as compared with the global array population. Additionally, global term-to-parents analysis was conducted on the whole group of array-represented GO terms, to compare each term to each of its direct parent terms, and to its GO tree root (i.e MF/BP). This specific analysis was conducted using KS, Fisher exact, Kruskal-Wallis and variance tests.
MG-thymoma exon array permutated data set
To perform permutations, the median fold changes of the thymus samples were mixed twice. Then, log2 ratio between the mixed datasets was calculated. Continuous and discrete analyses were performed on the MG-thymoma permutated data (results under Supplementary Material). KS, variances and Kruskal-Wallis tests also served to examine specific changes in GO categories compared to their direct and indirect parent GO terms.
Database construction
A MySQL database was constructed and used to store exon array expression signals at the exon probe-set level, as well as annotation data from the analyzed samples, in corresponding tables, for efficient transcript-specific queries.
Other applications
An upper layer Java program was used to access specific transcripts information. To examine global exonic and gene-level signals at different gene fragments, a Visual Basic application was written. Matlab 7.1.0.246–R14 [89] used to perform all statistical analyses.
Immunohistochemistry
Polyclonal antibodies for SC35, Myosin (Sigma, St. Louis, MI) and AS/SF2 (Zymed, San Francisco, CA) were used at 1[ratio]100, 1[ratio]100, 1[ratio]20 dilutions, respectively. Sections were deparaffinized, permeabilized and incubated with 100 mM Glycine in PBS for 20 min at room temp, preblocked with buffer containing 5% donkey serum, 0.5% Tween20 in PBS (1 h, at room temp) and incubated with primary antibodies (overnight, at 4°C). Biotinylated antibodies were incubated with Cy3-conjugated streptavidin (Jackson ImmunoResearch Laboratories, West Grove PA, USA). Sections were coverslipped and analyzed by confocal microscopy using a Bio-Rad MRC-1024 scanhead (Hemel Hempsted, Hertfordshire, U.K.) equipped with a digital camera and Olympus FV-1000 confocal microscopes, using excitation and emission parameters suitable for Cy3. Four areas (54 μ2) were photographed from each section with SC35 and ASF/SF2 labeling and the mean density per area was quantified with the software package ImagePro4 (Media Cybernetics, Silver Spring, MD). Myosin immunohistochemistry was performed on 106μ2 sections and the same software was used to analyze the number of stained cells per area. Student's t-test was used to determine the statistical significance between healthy and MG-thymoma sections.
Fluorescence In Situ Hybridization (FISH)
Deparaffinization and rehydration of the tissue, permeabilization by proteinase K and prehybridization were as detailed elsewhere [39]. Following prehybridization for 30 min, at 60°C with hybridization buffer (50% formamide, 750 mmol/L sodium chloride, 75 mmol/L sodium citrate at pH 4.5, 50 µg/mL heparin and 50 μg/mL tRNA), hybridization was performed for (2h, 52°C) with 1 µg/mL 5′-biotinylated, 2-O-methylated ACHE cRNA probe complementary to human AChE-R mRNA (Microsynth GMBH (Balgach, Switzerland)). Microscopy and data analysis involved four 106μ2 areas from each section and stained cell numbers per area were determined.
Real-time RT-PCR
For each sample, 0.4 µg RNA was used for 20 µl cDNA synthesis using Promega RT-PCR kit (Promega, Madison, WI). Real-time RT-PCR was performed in triplicate for each sample using ABI prism 7900HT and SYBR green master mix (Applied Biosystems, Foster City, CA). ROX, a passive reference dye, was used for signal normalization across the plate. Primer sequences are described under Table S5. Annealing temperature was 60° C for all primers. Serial dilution of samples served to evaluate primers efficiency and the appropriate cDNA concentration that yields linear changes. Melting curve analysis and amplicon sequencing verified the end product and β-actin served as reference gene.
* Additional Materials and methods are under Text S5.
Figure S1
The number of GO categories presenting discrete and continuous changes in MG-thymoma by Venn diagrams. BP and MF categories that presented discrete (denoted as D) 2-fold change (dark gray) or continuous (denoted as C) change of median transcript exonic expression level using KS statistics (light gray) and both methods (intersection areas) as compared with the total population of UniGene clusters represented on the array. Note that in both MF and BP, more categories decreased than increased, and more categories showed change in the continuous approach than the discrete.
(0.14 MB TIF)
Figure S2
Tumor-specific Gene and Exon Level Expression Changes. Exon level probe sets showed a decrease fold change trend in MG-thymoma compared to healthy thymus (Ai). In colon cancer, an inverse increase trend appeared compared to healthy colon data (Aii). In both, the trend was conserved across all annotation levels-core, extended and full (Ai and Aii). Specifically, core level exons decreased in MG-thymoma compared to colon tumorgenesis events (Aiii). Median gene-level global exon array population exhibited decrease in MG-thymoma tissues compared to healthy thymuses, corresponding to exon-level changes (Aiv). The change was significant and differed from that of permutated populations (Figure S3). (B) The center 80% exons of all transcripts showed larger expression decrease than both 3′ and 5′ 10% portions (statistical information under Supplementary Material). (C) Focusing only at terminal probes, the 3′ of MG-thymoma samples exhibited decrease of the exons in the 3′ 60 bps, compared to the 600 bps region (low KS P-value <0.05), with a change in dispersion (variances test P-value = 0; exon data was included if at least half of it was within the tested transcript boundaries). (D) Exonic changes were slightly different between 3′ to the 5′ 10% genomic region of all transcripts. 3′ edge increased pronouncedly with changes both in location (i) and in the number of genes with changed exons (ii). (E) At the 5% genomic region, the 3′ edge regions decreased compared to the 5′, with a difference in location and dispersion (i) and the number of changed genes (ii). (F) The 2.5% fragment resolution revealed a striking difference in exonic change patterns between the 3′ to the 5′ edges, expressed in distributional tails, location and dispersion (i) as well as the number of changed genes (ii).
(1.17 MB TIF)
Figure S3
Comparison of total global median core exons change in MG-thymoma and colon cancer. A) The median core exonic gene level signal is shown for MG-thymoma and colon cancer, for all the UniGene clusters represented on the array. Generally, colon cancer (N = 10) increased compared to MG-thymoma changes (N = 4) significantly (high KS P-value = 0). MG-thymoma and colon cancer samples were compared to matching healthy samples accordingly, and then to one another. B) (i) Median core exonic gene level signal, for MG-thymoma compared to healthy thymus samples (blue), with permutated patients and healthy samples changes (green and red). (ii) Median core exonic gene level signal, for colon cancer compared to healthy colon samples (blue), with permutated patients and healthy samples changes (green and red).
(0.63 MB TIF)
Figure S4
Comparison of median expression change in MG-thymoma 3′ 60 to 600 base pairs. Median exonic change of all array transcripts, was considerably smaller within the 3′ 60 nucleotides (N = 2,131) then in the 3′ 600 bps (N = 16,318). Statistical information under Supplementary Material.
(0.36 MB TIF)
Figure S5
Comparison between expression differences in various gene edges between the 3′ to 5′ of genes. A. MG-thymoma compared to healthy thymus samples (i)Median Exonic change of 3′ compared to 5′ 10% edge fragments of all array transcripts. There was a slight increase (CDF plot) in the 5′ Exonic change (high KS<0.05) with a change in location and dispersion. (ii) Median Exonic change of 3′ compared to 5′ 5% edge fragments of all array transcripts. There was a slight decrease (CDF plot) in the 5′ Exonic change (high KS<0.05) with a change in location and dispersion. (iii) Median Exonic change of 3′ compared to 5′ 2.5% edge fragments of all array transcripts. A striking difference between edges is observed, at both distributional tails (high and low KS P-values = 0), and both dispersion and location. (iv) In the 5′ edge, no change between median exonic changes observed between 10%, 5% and 2.5% of all the transcripts. B. Colon cancer compared to healthy colon samples Median Exonic change of 3′ compared to 5′ 2.5% edge fragments of all array transcripts. There was a decrease (CDF plot, low KS P-value = 0.05) in the 5′ Exonic change compared to the 3′ edge.
(0.56 MB TIF)
Figure S6
Specific GO category change compared to its parent terms. The change in RNA binding (N = 83) category compared to both direct and indirect GO parents. The blue and red bars indicate UniGenes that decrease and increased more then 2-fold, accordingly. (i) RNA binding decreased (low KS P-value <0.05) compared to the global parent term, MF (N = 21,047). (ii) RNA binding decreased (low KS P-value <0.05) also compared to its direct parent term, nucleic acid binding (N = 280).
(0.60 MB TIF)
Figure S7
Median core exons change of ASF/SF2, SC35, Myosins and AChE-R. The median core exonic log fold change as compared between MG-thymoma to healthy thymus samples, for the validated genes. Myosin (MYH10), lymphocyte-specific myosin (MYLC2PL) and AChE-R increased, whereas SC-35 and ASF/SF2 decreased.
(0.05 MB TIF)
Text S1
Functional Analysis of Colon Cancer Data Set Exhibits Large Overlaps with Other Colon Cancer Data Sets. Results of comparisons between our continuous and discrete ad-hoc functional GO statistical analysis to other ad- and post- hoc functional GO analyses on colon cancer microarray and proteomic data sets.
(0.10 MB DOC)
Text S2
Global Exons Probe Sets Changes in Different Gene Portions of MG-Thymoma and Colon Cancer. Statistical results of the comparisons between different gene edges (3′ and 5′ regions) expression changes between MG-thymoma to healthy thymuses, and differs from permutated MG-thymoma data set.
(0.03 MB DOC)
Text S4
The Intron in which the New ACHE Exon is Located is Enriched with ALu Repeats. Results of repeat masker [53] on the constitutive ACHE exons number 2 and 3, intron 2–3 and intron 3–4 (where the new exon is located).
(0.04 MB DOC)
Text S3
Core Probe Sets Normalized Signals Intensity of Detected MG-Thymoma genes. Expression signals intensity of core probe sets of the MG-thymoma genes detected by the specific term to parent ad-hoc approach combined with fold change threshold are given for MG-thymoma and healthy thymuses.
(0.09 MB DOC)
Text S5
(0.04 MB DOC)
DataSet S1
1D-Gel Mass Spectrometry Proteomic Analysis Results on the MG-Thymoma and Healthy Thymus Samples. All the identified peptides are given, with the corresponding proteins identified by clustering analysis and NCBI database [4]
(1.72 MB XLS)
Table S1
Ad-hoc Global Functional BP and MF GO Analysis of Exon Array Colon Cancer Data. Results of Affymetrix exon array colon cancer data set [20] are given for MF and BP. The columns of the Excel table are as indicated: the name of GO term, its GO ID, p-values of the continuous method (KS-P high tail test), testing the hypothesis that the tested distribution contains larger values than the global distribution, of Fisher exact test (Fishex INC, the high tail test) using the hypergeometric distriution (i.e, the discrete method), testing the hypothesis that the tested distribution contains larger than expected number of increased (INC) genes (using a 2-fold cutoff), the KS-P (low tail) testing the hypothesis that the distribution contains smaller values than those observed with the global distribution and Fishex (DEC) for testing the hypothesis that the testes distribution contain larger than expected number of decreased (DEC) genes (using a 2-fold cutoff). N is The number of transcripts associated with the GO term, KS accur (KS accuracy) is a number indicating the reliability of the KS test. The p-value is most accurate when KS accur >4. Additionaly, the percent of transcripts changed above the threshold is given for each category (named % changed genes), and the number of genes changed more then the threshold (named #changed genes). The red and blue cells in the tables indicate the GO terms that significantly increased or decreased, respectively (at significance level of p-value <0.05).
(0.62 MB XLS)
Table S2
Ad-hoc Global Functional BP and MF GO Analysis of Exon Array MG-Thymoma Data Set. Results of Affymetrix exon array MG-thymoma data set are given for BP and MF. The columns of the Excel table are as follows: Name (GO term title) ,GO ID, KS-P (high), Fishex (INC),KS-P (low),Fishex (DEC), KS-P (high), percent changed genes and number of changed genes. The red and blue cells in the tables indicate the GO terms that significantly increased or decreased, respectively (p<0.05). Detailed description of each column is given under S1 description.
(0.37 MB XLS)
Table S3
Specific, Term-To-Parent Functional GO Analysis Results on MG-Thymoma Data Set. Results of hierarchical comparison between GO terms to their direct and indirect (BP/MF) parent GO terms in MG-thymoma exon array data set are given for all the terms represented on Affymetrix exon 1.0 S_T array. The columns of the Excel table are: Name (of GO term), GO ID (of the term), Parent name (the name and GO ID of the compared parent, KS-P (high): p-value for the one tailed KS test (ie, the continuous method), testing the hypothesis that the tested distribution contains larger values than the global distribution, Fishex (INC): p-value for the Fisher exact test using the hypergeometric distribution (ie, the discrete method), testing the hypothesis that the tested distribution contains a larger than expected number of increased (INC) genes (using a 2-fold cutoff), KS-P (low)-a p-value for the one tailed KS test (ie, the continuous method), testing the hypothesis that the tested distribution contains smaller values than those observed with the global distribution, Fishex (DEC): a p-value for the Fisher exact test using the hypergeometric distribution (ie, the discrete methods), testing the hypothesis that the testes distribution contain larger than expected number of decreased (DEC) genes (using a 2-fold cutoff), N-the number of transcripts associated with the GO term, KS accur (KS accuracy)-a number indicating the reliability of the KS test. The p- value is most accurate when KS accur >4.VAR: P value for variances (VAR) test indicating a change in dispersion and of Kruskal Wallis (KW) test indicate a change in location. The percent of transcripts that changed more than the threshold (both increased and decreased) of all the GO term transcripts (% change genes), the number of changed genes (# changed genes)-the number of transcripts that changed more than the threshold (both increased and decreased) out of all the GO term transcripts. The red and blue cells in the tables indicate the GO terms that significantly increased or decreased, respectively, at significance level of 0.05.
(5.76 MB XLS)
Table S4
Samples Description of MG-Thymoma and Healthy Thymus. Detailed description of the MG-thymoma and healthy thymus data set.
(0.03 MB XLS)
Table S5
PCR Primers for ACHE New Exon. PCR primers design obtained from Primer3 software (www.frodo.wi.mit.edu/) and were used for both gel electrophoration of RT-PCR and for Real-Time RT-PCR.
(0.03 MB XLS)
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the European Alternative Splicing Network of Excellence-EURASNET LSH-2004-1.1.5-3 # 518238, LSHM-CT-2006-037378, EU LSHG-CT-2006-037277, The German Israel Project DIP-G 3.2, United States-Israel Binational Science Foundation (BSF No. 2003028-01), Israel Ministry of Science and Technology grant number 3-2589, Israel Science Foundation, Grant No. 399/07 and The Eric Roland Center for neurodegenerative diseases.
1. Buratti E, Baralle FE. Another step forward for SELEXive splicing. Trends Mol Med. 2005;11:5–9. [PubMed]
2. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer. 2005;42:342–357. [PubMed]
3. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 2002;18:186–193. [PubMed]
4. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 2003;302:2141–2144. [PubMed]
5. Zavolan M, Kondo S, Schonbach C, Adachi J, Hume DA, et al. Impact of alternative initiation, splicing, and termination on the diversity of the mRNA transcripts encoded by the mouse transcriptome. Genome Res. 2003;13:1290–1300. [PubMed]
6. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J. Genome-wide analysis of alternative pre-mRNA splicing. J Biol Chem 2007
7. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, et al. Function of alternative splicing. Gene. 2005;344:1–20. [PubMed]
8. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet. 2002;30:13–19. [PubMed]
9. Kan Z, Rouchka EC, Gish WR, States DJ. Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res. 2001;11:889–900. [PubMed]
10. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol. 2007;8:R64. [PMC free article] [PubMed]
11. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000;96:3872–3879. [PubMed]
12. Marie J, Wakkach A, Coudray A, Chastre E, Berrih-Aknin S, et al. Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients. J Immunol. 1999;162:2103–2112. [PubMed]
13. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–2854. [PMC free article] [PubMed]
14. Stremmel C, Dango S, Thiemann U, Kayser G, Passlick B. [Thymoma–incidence, classification and therapy]. Dtsch Med Wochenschr. 2007;132:2090–2095. [PubMed]
15. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2:797–804. [PubMed]
16. Friedman N. Inferring cellular networks using probabilistic graphical models. Science. 2004;303:799–805. [PubMed]
17. Chee M, Yang R, Hubbell E, Berno A, Huang XC, et al. Accessing genetic information with high-density DNA arrays. Science. 1996;274:610–614. [PubMed]
19. Affymetrix Array Design for the GeneChip® Human Genome U133 Set
20. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics. 2006;7:325. [PMC free article] [PubMed]
21. Khatri P, Draghici S. Ontological analysis of gene expression data: current tools, limitations, and open problems. Bioinformatics. 2005;21:3587–3595. [PMC free article] [PubMed]
22. Dudoit S, et al. Multiple hypothesis testing in microarray experiments. Statistical Science. 2003;18:71–103.
23. Quackenbush J. Computational approaches to analysis of DNA microarray data. Methods Inf Med. 2006;45(Suppl 1):91–103.
24. Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70. [PMC free article] [PubMed]
25. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, et al. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003;4:R7. [PMC free article] [PubMed]
26. Nilsson B, Hakansson P, Johansson M, Nelander S, Fioretos T. Threshold-free high-power methods for the ontological analysis of genome-wide gene expression studies. Genome Biol. 2007;8:R74. [PMC free article] [PubMed]
27. Ben-Shaul Y, Bergman H, Soreq H. Identifying subtle interrelated changes in functional gene categories using continuous measures of gene expression. Bioinformatics. 2005;21:1129–1137. [PubMed]
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. [PubMed]
29. Yang D, Li Y, Xiao H, Liu Q, Zhang M, et al. Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics. 2008;24:265–271. [PubMed]
30. Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics. 2005;21:1943–1949. [PubMed]
31. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004;20:1464–1465. [PubMed]
32. Breslin T, Eden P, Krogh M. Comparing functional annotation analyses with Catmap. BMC Bioinformatics. 2004;5:193. [PMC free article] [PubMed]
33. Lee HK, Braynen W, Keshav K, Pavlidis P. ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics. 2005;6:269. [PMC free article] [PubMed]
34. Meshorer E, Toiber D, Zurel D, Sahly I, Dori A, et al. Combinatorial complexity of 5′ alternative acetylcholinesterase transcripts and protein products. J Biol Chem. 2004;279:29740–29751. [PubMed]
35. Bush CR, Havens JM, Necela BM, Su W, Chen L, et al. Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPARgamma ) and calcium signaling in human colorectal cancer cells. J Biol Chem 2007
36. Maglietta R, Piepoli A, Catalano D, Licciulli F, Carella M, et al. Statistical assessment of functional categories of genes deregulated in pathological conditions by using microarray data. Bioinformatics 2007
37. Patel BB, Li XM, Dixon MP, Blagoi EL, Seeholzer SH, et al. Searchable high-resolution 2D gel proteome of the human colon crypt. J Proteome Res. 2007;6:2232–2238. [PubMed]
38. Gilboa-Geffen A, Lacoste PP, Soreq L, Cizeron-Clairac G, Le Panse R, et al. The thymic theme of acetylcholinesterase splice variants in myasthenia gravis. Blood. 2007;109:4383–4391. [PubMed]
39. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, et al. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. Faseb J. 2003;17:214–222. [PubMed]
40. Wu F, Chakravarti S. Differential Expression of Inflammatory and Fibrogenic Genes and Their Regulation by NF-{kappa}B Inhibition in a Mouse Model of Chronic Colitis. J Immunol. 2007;179:6988–7000. [PubMed]
41. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984;44:753–760. [PubMed]
42. Havana Vega Transcript Report-HLA-DRB1-002
43. Espejo F, Patarroyo ME. Determining the 3D structure of human ASC2 protein involved in apoptosis and inflammation. Biochem Biophys Res Commun. 2006;340:860–864. [PubMed]
44. Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, et al. Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology. 2006;68:1360–1365. [PubMed]
45. Mohan S, Barohn RJ, Jackson CE, Krolick KA. Evaluation of myosin-reactive antibodies from a panel of myasthenia gravis patients. Clin Immunol Immunopathol. 1994;70:266–273. [PubMed]
46. Mesnard-Rouiller L, Bismuth J, Wakkach A, Poea-Guyon S, Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J Neuroimmunol. 2004;148:97–105. [PubMed]
47. Smith CW, Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci. 2000;25:381–388. [PubMed]
48. Singh NN, Androphy EJ, Singh RN. The regulation and regulatory activities of alternative splicing of the SMN gene. Crit Rev Eukaryot Gene Expr. 2004;14:271–285. [PubMed]
49. Bai Y, Lee D, Yu T, Chasin LA. Control of 3′ splice site choice in vivo by ASF/SF2 and hnRNP A1. Nucleic Acids Res. 1999;27:1126–1134. [PMC free article] [PubMed]
50. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet. 2008;24:7–10. [PubMed]
51. Affymetrix Human exon array tissue mixture data set. Affymetrix
52. Xiong Z, Shaibani A, Li YP, Yan Y, Zhang S, et al. Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle. J Clin Pathol. 2006;59:855–861. [PMC free article] [PubMed]
53. Smit A, Hubley R, Green P. RepeatMasker Open-3.0. <Error! Hyperlink reference not valid. 1996–2004
54. Sorek R, Ast G, Graur D. Alu-containing exons are alternatively spliced. Genome Res. 2002;12:1060–1067. [PubMed]
55. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001;17:100–107. [PubMed]
56. Beer I, Barnea E, Ziv T, Admon A. Improving large-scale proteomics by clustering of mass spectrometry data. Proteomics. 2004;4:950–960. [PubMed]
57. Vandermoere F, El Yazidi-Belkoura I, Slomianny C, Demont Y, Bidaux G, et al. The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem. 2006;281:14307–14313. [PubMed]
58. Tsukita S, Yonemura S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci. 1997;22:53–58. [PubMed]
59. Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics. 2006;22:1600–1607. [PubMed]
60. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics. 2007;23:257–258. [PubMed]
61. Yang D, Li Y, Xiao H, Liu Q, Zhang M, et al. Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics 2007
62. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14:185–193. [PubMed]
63. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004;64:7647–7654. [PubMed]
64. Wang Z, Lo HS, Yang H, Gere S, Hu Y, et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 2003;63:655–657. [PubMed]
65. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 2003;31:5635–5643. [PMC free article] [PubMed]
66. Franciotta D, Cuccia M, Dondi E, Piccolo G, Cosi V. Polymorphic markers in MHC class II/III region: a study on Italian patients with myasthenia gravis. J Neurol Sci. 2001;190:11–16. [PubMed]
67. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, et al. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol. 1993;47:115–122. [PubMed]
68. Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 2001;57:1555–1560. [PubMed]
69. Yoshida T, Tsuchiya M, Ono A, Yoshimatsu H, Satoyoshi E, et al. HLA antigens and myasthenia gravis in Japan. J Neurol Sci. 1977;32:195–201. [PubMed]
70. Mourra N, Zeitoun G, Buecher B, Finetti P, Lagarde A, et al. High frequency of chromosome 14 deletion in early-onset colon cancer. Dis Colon Rectum. 2007;50:1881–1886. [PubMed]
71. Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–387. [PubMed]
72. Nerenberg PS, Salsas-Escat R, Stultz CM. Collagen-a necessary accomplice in the metastatic process. Cancer Genomics Proteomics. 2007;4:319–328. [PubMed]
73. Mio F, Chiba K, Hirose Y, Kawaguchi Y, Mikami Y, et al. A Functional Polymorphism in COL11A1, Which Encodes the alpha 1 Chain of Type XI Collagen, Is Associated with Susceptibility to Lumbar Disc Herniation. Am J Hum Genet. 2007;81:1271–1277. [PubMed]
74. Kuroda K, Okamoto O, Shinkai H. Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. J Invest Dermatol. 1999;112:706–710. [PubMed]
75. Bjarnadottir TK, Geirardsdottir K, Ingemansson M, Mirza MA, Fredriksson R, et al. Identification of novel splice variants of Adhesion G protein-coupled receptors. Gene. 2007;387:38–48. [PubMed]
76. Adamowicz M, Radlwimmer B, Rieker RJ, Mertens D, Schwarzbach M, et al. Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer. 2006;45:829–838. [PubMed]
77. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med. 2006;354:1370–1377. [PubMed]
78. Meshorer E, Soreq H. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 2006;29:216–224. [PubMed]
79. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, et al. Estrogen inhibits cell proliferation through in situ production in human thymoma. Clin Cancer Res. 2005;11:6495–6504. [PubMed]
80. Affymetrix. Gene Signal Estimates from Exon arrays. Affymetrix GeneChip Exon Array WhitePaper Collection. 2005
81. Parra G, Blanco E, Guigo R. GeneID in Drosophila. Genome Res. 2000;10:511–515. [PubMed]
82. Burge C, Karlin S. Prediction of complete gene structures in human genomic DNA. J Mol Biol. 1997;268:78–94. [PubMed]
83. Gross SS, Brent MR. Using multiple alignments to improve gene prediction. J Comput Biol. 2006;13:379–393. [PubMed]
84. Mignone F, Grillo G, Liuni S, Pesole G. Computational identification of protein coding potential of conserved sequence tags through cross-species evolutionary analysis. Nucleic Acids Res. 2003;31:4639–4645. [PMC free article] [PubMed]
85. Carter RJ, Dubchak I, Holbrook SR. A computational approach to identify genes for functional RNAs in genomic sequences. Nucleic Acids Res. 2001;29:3928–3938. [PMC free article] [PubMed]
86. Parra G, Agarwal P, Abril JF, Wiehe T, Fickett JW, et al. Comparative gene prediction in human and mouse. Genome Res. 2003;13:108–117. [PubMed]
87. Korf I, Flicek P, Duan D, Brent MR. Integrating genomic homology into gene structure prediction. Bioinformatics. 2001;17(Suppl 1):S140–148. [PubMed]
88. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–29. [PubMed]
89. Mathworks. MATLAB. In.,The Mathworks,7.0.4.365 (R14) Service Pack 2 Ed.,Incorporated Copyright 1984–2005. 2005
90. Birney E, Andrews D, Bevan P, Caccamo M, Cameron G, et al. Ensembl 2004. Nucleic Acids Res. 2004;32:D468–470. [PMC free article] [PubMed]
91. Slater GS, Birney E. Automated generation of heuristics for biological sequence comparison. BMC Bioinformatics. 2005;6:31. [PMC free article] [PubMed]
92. Vaughn MW, Martienssen R. It's a small RNA world, after all. Science. 2005;309:1525–1526. [PubMed]
Articles from PLoS ONE are provided here courtesy of
Public Library of Science